ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Reaffirmed by HC Wainwright

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $94.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 53.97% from the stock’s current price.

A number of other brokerages have also recently weighed in on ANIP. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Truist Financial reaffirmed a “hold” rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $78.80.

ANI Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ:ANIP opened at $61.05 on Tuesday. The stock’s 50-day moving average is $61.25 and its 200 day moving average is $63.80. The company has a market cap of $1.28 billion, a PE ratio of 38.41 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. ANI Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. During the same quarter in the previous year, the company earned $1.06 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 18.5% on a year-over-year basis. Sell-side analysts anticipate that ANI Pharmaceuticals will post 3.5 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, COO Muthusamy Shanmugam sold 20,000 shares of the business’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $58.90, for a total value of $1,178,000.00. Following the completion of the transaction, the chief operating officer now owns 682,620 shares in the company, valued at $40,206,318. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have sold 66,007 shares of company stock worth $4,089,790. Insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently modified their holdings of ANIP. Vanguard Group Inc. grew its holdings in ANI Pharmaceuticals by 1.4% during the first quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock valued at $90,314,000 after purchasing an additional 17,460 shares during the period. Rubric Capital Management LP grew its stake in shares of ANI Pharmaceuticals by 32.8% during the 4th quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after acquiring an additional 277,989 shares during the period. Dimensional Fund Advisors LP increased its holdings in ANI Pharmaceuticals by 3.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock worth $40,132,000 after acquiring an additional 21,053 shares in the last quarter. Ranger Investment Management L.P. raised its stake in ANI Pharmaceuticals by 1.8% during the 4th quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock worth $23,965,000 after acquiring an additional 7,769 shares during the period. Finally, Millennium Management LLC lifted its holdings in ANI Pharmaceuticals by 1,005.8% during the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after purchasing an additional 209,272 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.